{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=10",
    "query": {
      "intervention": "Dose Level -1",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 29129,
    "total_pages": 2913,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T22:49:12.891Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00363142",
      "title": "A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection",
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Half-boosted Fosamprenavir",
          "type": "DRUG"
        },
        {
          "name": "Full Boosted Fosamprenavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2006-05",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2010-11-05",
      "last_synced_at": "2026-11-18T22:49:12.891Z",
      "location_count": 49,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 39 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00363142"
    },
    {
      "nct_id": "NCT04327986",
      "title": "Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Histologically or Cytologically Confirmed Pancreatic Cancer",
        "Unresectable or Borderline Resectable Pancreatic Cancer",
        "Pancreatic Neoplasms",
        "Pancreatic Cancer",
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "M7824",
          "type": "DRUG"
        },
        {
          "name": "M9241",
          "type": "DRUG"
        },
        {
          "name": "SBRT",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2021-06-15",
      "completion_date": "2022-02-03",
      "has_results": true,
      "last_update_posted_date": "2022-05-18",
      "last_synced_at": "2026-11-18T22:49:12.891Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04327986"
    },
    {
      "nct_id": "NCT00344786",
      "title": "Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-Cell Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "CNF2024 (BIIB021)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2006-02",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2009-06-05",
      "last_synced_at": "2026-11-18T22:49:12.891Z",
      "location_count": 3,
      "location_summary": "San Diego, California • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00344786"
    },
    {
      "nct_id": "NCT02198170",
      "title": "A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ketoconazole-placebo",
          "type": "DRUG"
        },
        {
          "name": "placebo-ketoconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2011-02",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2015-02-13",
      "last_synced_at": "2026-11-18T22:49:12.891Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02198170"
    },
    {
      "nct_id": "NCT06636383",
      "title": "Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glycogen Storage Disease Type Ia"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2024-11-04",
      "completion_date": "2036-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-11-18T22:49:12.891Z",
      "location_count": 9,
      "location_summary": "Orange, California • Denver, Colorado • Hartford, Connecticut + 6 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06636383"
    },
    {
      "nct_id": "NCT02914405",
      "title": "Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ch14.18/CHO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Hospital Southampton NHS Foundation Trust",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Year to 99 Years"
      },
      "enrollment_count": 44,
      "start_date": "2018-05-24",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-11-18T22:49:12.891Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02914405"
    },
    {
      "nct_id": "NCT02035605",
      "title": "A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "ALN-AT3SC",
          "type": "DRUG"
        },
        {
          "name": "Sterile Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 51,
      "start_date": "2014-01-20",
      "completion_date": "2017-07-20",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-11-18T22:49:12.891Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02035605"
    },
    {
      "nct_id": "NCT05797805",
      "title": "A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tegavivint",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Iterion Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2023-09-13",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-11-18T22:49:12.891Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Miami, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797805"
    },
    {
      "nct_id": "NCT02902679",
      "title": "A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Thrombosis",
        "Factor XI",
        "Renal Impairment",
        "ESRD (End-Stage Renal Disease)"
      ],
      "interventions": [
        {
          "name": "BMS-986177",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2016-11",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2017-07-27",
      "last_synced_at": "2026-11-18T22:49:12.891Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02902679"
    },
    {
      "nct_id": "NCT01288079",
      "title": "A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "TC-5214",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 145,
      "start_date": "2011-02",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2012-11-20",
      "last_synced_at": "2026-11-18T22:49:12.891Z",
      "location_count": 25,
      "location_summary": "Beverly Hills, California • Chino, California • Garden Grove, California + 22 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01288079"
    }
  ]
}